Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07241234 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Subjects With Phenylketonuria
A Phase 1 study, sponsored by Agios Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT07241234 is a Phase 1 study that is actively recruiting participants, run by Agios Pharmaceuticals. The registered enrollment target is 20 participants.
The verdict
NCT07241234, a Phase 1 study, is actively recruiting participants, sponsored by Agios Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The primary purpose of this study is to assess the safety and tolerability of AG-181 in subjects with Phenylketonuria (PKU).
Interventions
- DRUG AG-181
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-04-17 |
| Est. Completion | 2028-01-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07241234
The ClinicalTrials.gov registry entry for NCT07241234 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Agios Pharmaceuticals, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AG-181 is the first listed.
NCT07241234 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07241234 about?
NCT07241234 is a clinical study titled "A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Subjects With Phenylketonuria". The primary purpose of this study is to assess the safety and tolerability of AG-181 in subjects with Phenylketonuria (PKU).
What is the current status of trial NCT07241234?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2026-04-17. Estimated completion is 2028-01-17.
What interventions are being tested in trial NCT07241234?
The interventions under investigation include: AG-181 (DRUG).
Who is sponsoring clinical trial NCT07241234?
This trial is sponsored by Agios Pharmaceuticals, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.